

## UC Irvine

### UC Irvine Previously Published Works

**Title**

Enantioselective Addition of  $\alpha$ -Nitroesters to Alkynes

**Permalink**

<https://escholarship.org/uc/item/1hb4t3bb>

**Journal**

Angewandte Chemie International Edition, 60(9)

**ISSN**

1433-7851

**Authors**

Davison, Ryan T  
Parker, Patrick D  
Hou, Xintong  
et al.

**Publication Date**

2021-02-23

**DOI**

10.1002/anie.202014015

Peer reviewed



Published in final edited form as:

Angew Chem Int Ed Engl. 2021 February 23; 60(9): 4599–4603. doi:10.1002/anie.202014015.

## Enantioselective Addition of $\alpha$ -Nitroesters to Alkynes


Ryan T. Davison, Patrick D. Parker, Xintong Hou, Crystal P. Chung, Sara A. Augustine, Vy M. Dong

Department of Chemistry, University of California, Irvine, Irvine, CA 92697 (USA)

### Abstract

By using Rh-H catalysis, we couple  $\alpha$ -nitroesters and alkynes to prepare  $\alpha$ -amino acid precursors. This atom-economical strategy generates two contiguous stereocenters, with high enantio- and diastereocontrol. In this transformation, the alkyne undergoes isomerization to generate a Rh(III)- $\pi$ -allyl electrophile, which is trapped by an  $\alpha$ -nitroester nucleophile. A subsequent reduction with In powder transforms the allylic  $\alpha$ -nitroesters to the corresponding  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino esters.

### Graphical Abstract



Making alkyne C–C bonds. An enantioselective Rh-catalyzed addition of  $\alpha$ -nitroesters to alkynes affords access to  $\alpha$ -amino acid precursors containing contiguous stereocenters. These motifs can be further transformed into  $\alpha$ -amino esters without stereoablation.

### Keywords

rhodium-hydride; tandem catalysis; amino acid; nitroester; alkyne

By designing and synthesizing  $\alpha$ -amino acids ( $\alpha$ -AAs), chemists have expanded the genetic code, shed light on protein function, and enabled innovative medical applications.<sup>[1–3]</sup> The  $\alpha,\alpha$ -disubstituted  $\alpha$ -AAs and related analogs attract interest due to their metabolic stability, unique conformations, and potent bioactivity (Figure 1).<sup>[4]</sup> Enantioenriched  $\alpha,\alpha$ -disubstituted  $\alpha$ -AAs are targeted by various strategies, including phase-transfer catalysis, organocatalysis, and transition-metal catalysis.<sup>[5]</sup> Despite an interest in these motifs, methods for the enantio- and diastereoselective preparation of  $\alpha,\alpha$ -disubstituted  $\alpha$ -AAs bearing contiguous stereocenters remain sought after;<sup>[6]</sup> emerging reports feature pre-functionalized allylic partners. The direct addition of an amino acid surrogate to a  $\pi$ -system represents an attractive approach to  $\alpha,\alpha$ -disubstituted  $\alpha$ -AAs. Towards this end, Zi and coworkers exploited synergistic Pd/Cu catalysis for the stereodivergent coupling of aldimine

dongv@uci.edu.

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:

esters and 1,3-dienes.<sup>[7]</sup> In a complementary approach, we propose using a Rh-hydride (Rh-H) catalyst to couple  $\alpha$ -nitrocarbonyls and alkynes to generate the corresponding  $\alpha$ -AA precursors. This atom-economical<sup>[8]</sup> coupling exploits two simple functional groups and provides rapid access to synthons for the building blocks of life.<sup>[9]</sup>

On the basis of literature precedent,<sup>[10]</sup> we envisioned a tandem catalytic cycle for the asymmetric coupling of  $\alpha$ -nitrocarbonyls **1** and alkynes **2** to yield  $\alpha$ -AA synthons **3** (Figure 2). Wolf and Werner discovered that Rh-H complexes isomerize alkynes (**2**) via an allene intermediate (**4**) to form Rh- $\pi$ -allyl species **IV**.<sup>[11]</sup> By using this isomerization, the Breit laboratory achieved asymmetric and catalytic couplings of alkynes with a wide-range of heteroatom nucleophiles to afford branched allylic products.<sup>[12]</sup> In comparison, the analogous coupling of alkynes with carbon nucleophiles remains more limited, with only three asymmetric variants.<sup>[13]</sup> We previously reported that aldehydes couple to alkynes with high enantio- and diastereoselectivity when using a chiral Rh-H catalyst in synergy with a chiral amine co-catalyst.<sup>[13a]</sup> Xing and coworkers expanded this approach for the coupling of ketones with alkynes, however, an achiral amine co-catalyst furnishes the branched products with little to no diastereocontrol.<sup>[13c]</sup>

In related studies, we and Breit independently reported that 1,3-dicarbonyls can couple to alkynes to generate branched allylic carbonyl motifs.<sup>[14]</sup> Promising reactivity and regioselectivity has been achieved. However, obtaining high levels of enantio- and diastereoselectivity has been challenging. It occurred to us that  $\alpha$ -nitrocarbonyls display comparable chelation aptitude<sup>[15]</sup> and acidity ( $pK_a = ca. 8$ )<sup>[16]</sup> to 1,3-dicarbonyls. Thus, we imagined  $\alpha$ -nitrocarbonyls would be suitable nucleophiles for trapping Rh- $\pi$ -allyl species **IV**. With this design in mind, we set out to couple  $\alpha$ -nitrocarbonyls and alkynes with enantio- and diastereocontrol.

In initial studies, we discovered that various  $\alpha$ -nitrocarbonyls add to the commercially available alkyne **2a** (Table 1). Using a combination of  $[Rh(cod)Cl]_2$ , dppf, and diphenyl phosphate, we observe allylic  $\alpha$ -nitroketone,  $\alpha$ -nitroester, and  $\alpha$ -nitroamide products as single regioisomers (>20:1 *rr*) with moderate to high diastereoselectivity (5:1–12:1 *dr*).<sup>[17]</sup> In accordance with previous reports, there is a preference for the branched regioisomer, which bears two contiguous stereocenters.<sup>[10a-d,12–14]</sup> Our findings complement an enantioselective Pd-catalyzed  $\alpha$ -nitroester allylation reported by Ooi and coworkers.<sup>[18]</sup> In Ooi's study, the use of allylic carbonates affords linear regioisomers with one stereocenter.


Next, we focused on an enantioselective variant for the coupling of  $\alpha$ -nitroesters with alkynes because the resulting motifs are readily converted to  $\alpha$ -AAs.<sup>[19]</sup> To identify the appropriate chiral catalyst, we selected  $\alpha$ -nitroester **1a** and alkyne **2a** as the model substrates (Table 2). Using atropoisomeric bisphosphine ligands **L1–L3** with a range of dihedral angles,<sup>[20]</sup> we observe the allylic  $\alpha$ -AA precursor **3aa** with moderate yields (45–53%) and enantioselectivities (85:15–90:10 *er*). Ultimately, we found that commercial MeO-BIPHEP ligand **L6** affords **3aa** in 90% yield with 97:3 *er*, >20:1 *dr*, and >20:1 *rr* on preparative scale (1 mmol).<sup>[21,22]</sup> This coupling relies on the use of alkynes as the unsaturated partner instead of activated olefins, imines, propargylic carbonates, and allylic leaving groups.<sup>[18,19]</sup> Next, we explored the scope of this transformation to access unique  $\beta$ -aryl- $\alpha$ -nitroester motifs.

With this protocol, we explored the asymmetric coupling of various  $\alpha$ -nitroesters with **2a** (Table 3). Analogs of ethylalanine (**3ba**), leucine (**3da**), methionine (**3ea**), phenylalanine (**3fa**), 4-fluoro-phenylalanine (**3ga**), tyrosine (**3ha**), and tryptophan (**3ia**) are generated with moderate to high yields (34–84%) and excellent levels of enantioselectivity (95:5 *er*). The absolute configuration of **3fa** was confirmed by X-ray crystallographic analysis.<sup>[21,22]</sup> In the case of lower yielding substrates, we often recover  $\alpha$ -nitroester **1**.<sup>[21]</sup> The bulkier  $\beta$ -branched  $\alpha$ -nitroesters **1c** and **1j** do not couple to **2a** to form analogs of valine (**3ca**) and phenylglycine (**3ja**), respectively. Alkyl-substituted esters **3ka–3na** provide higher reactivity than aryl ester **3oa**. We see high levels of diastereocontrol (>20:1 *dr*) for forming **3ka** and **3la**, which suggests the C–C bond is forged by catalyst control.

Table 4 captures results from our study on the addition of **1a** to various alkynes **2**. Aryl alkynes possessing a variety of electronics and substitution patterns participate in the asymmetric coupling (**3ab–3al** and **3ao**). Alkynes bearing halides (**2b**, **2c**, **2h**, **2i** and **2l**), carbonyls (**2d** and **2f**), and extended  $\pi$ -systems (**2o**) transform to the corresponding allylic  $\alpha$ -nitroesters **3**. Aryl alkynes with electron-donating substituents (**1g** and **1j**) display lower conversion under standard conditions. Increasing the catalyst loading results in improved yields of **3ag** and **3aj** (88% and 96%, respectively), while maintaining high stereoselectivity (96:4 *er* and >20:1 *dr*). The presence of an ortho-substituent on alkyne **2l** imparts lower reactivity (46%), presumably due to steric hindrance. Pyridyl alkyne **2m** converts to allylic  $\alpha$ -nitroester **3am** with a higher catalyst loading. It appears that an aromatic or heteroaromatic substituent on the alkyne is critical for reactivity (see **3an**). The absolute configuration of **3ao** was confirmed by X-ray crystallographic analysis.<sup>[21,22]</sup>

Further experiments provide support for the mechanism depicted in Figure 2. First, we monitored a mixture of [Rh(cod)Cl]<sub>2</sub>, MeO-BIPHEP **L6**, and diphenyl phosphate by <sup>1</sup>H NMR spectroscopy.<sup>[21]</sup> We observe a resonance in the spectrum at –16.2 ppm. The observed resonance is consistent with reported values for Rh(III)-H complexes.<sup>[23]</sup> This resonance disappears in the <sup>1</sup>H NMR spectrum upon the addition of alkyne **2a**. Second, we subjected deuterated alkyne **d-2a** to the standard reaction conditions (Figure 3A). We observe deuterium scrambling into the  $\beta$ -,  $\gamma$ -, and  $\delta$ -positions of allylic  $\alpha$ -nitroester **d-3aa**. The incorporation of hydrogen atoms at the  $\delta$ -position of **d-3aa** supports reversible  $\beta$ -H elimination in the isomerization pathway. Third, to examine the plausibility of an allene intermediate in the catalytic cycle, we subjected 1-phenylallene (**4a**) to the standard conditions (Figure 3B). We observe **3aa** (14% yield) when using an excess of allene **4a**. Moreover, the remaining amount of allene **4a** is consumed. These results, which are in agreement with previous reports that suggest maintaining a low concentration of allene intermediate **4** slows competitive polymerization.<sup>[10i,12a,24,25]</sup>

Treating allylic  $\alpha$ -nitroester **3aa** with In powder readily yields the corresponding  $\alpha$ -amino ester **6** in 93% yield (eq 1). This simple reduction allows for rapid access to  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino esters that contain two contiguous stereocenters, without stereoablation.



(1)

The use of Rh-H catalysis offers an approach to novel  $\alpha$ -AAs. The allylic  $\alpha$ -AA precursors prepared contain an olefin handle that is attractive due to its potential use for protein modifications,<sup>[26]</sup> glycopeptide synthesis,<sup>[27]</sup> and cyclizations.<sup>[28]</sup> Our strategy offers a solution to the challenging preparation of contiguous stereocenters in an acyclic framework, with diastereo- and enantiocontrol. Insights from this study will guide development of related  $\alpha$ -nitrocarbonyl coupling reactions with alkynes. In particular, our laboratory has found initial success in the enantioselective addition of  $\alpha$ -nitroamides to alkynes, which could provide a way to couple peptides containing  $\alpha$ -nitroamide residues with alkynes.<sup>[21]</sup> Future studies will focus on widening scope and understanding the origins of stereocontrol. The high diastereocontrol achieved occurs without the need for a chiral amine (co-catalyst) as previously observed.<sup>[13a]</sup>

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

Funding provided by UC Irvine and the National Institutes of Health (R35GM127071). We thank Dr. Milan Gembicky (UC San Diego) for X-ray crystallographic analysis. We thank Solvias AG for donating commercial MeO-BIPHEP L6.

## References


- [1]. (a)de Graaf AJ; Kooijman M; Hennink WE; Mastrobattista E *Bioconjugate Chem* 2009, 20, 1281–1295.(b)Hodgson DRW; Sanderson JM *Chem. Soc. Rev* 2004, 33, 422–430. [PubMed: 15354223] (c)Hohsaka T; Sisido M *Curr. Opin. Chem. Biol* 2002, 6, 809–815. [PubMed: 12470735] (d)Hendrickson TL; de Crécy-Lagard V; Schimmel P *Annu. Rev. Biochem* 2004, 73, 147–176. [PubMed: 15189139] (e)Young DD; Schultz PG *ACS Chem. Biol* 2018, 13, 854–870. [PubMed: 29345901]
- [2]. Liu CC; Schultz PG *Annu. Rev. Biochem* 2010, 79, 413–444. [PubMed: 20307192]
- [3]. (a)Stevenazzi A; Marchini M; Sandrone G; Vergani B; Lattanzio M *Bioorg. Med. Chem. Lett* 2014, 24, 5349–5356. [PubMed: 25455481] (b)Blaskovich MA T. *J. Med. Chem* 2016, 59, 10807–10836.
- [4]. (a)Tanaka M *Chem. Pharm. Bull* 2007, 55, 349–358.(b)Aceña JL; Sorochinsky AE; Soloshonok VA *Synthesis* 2012, 44, 1591–1602.(c)Porter MR; Xiao H; Wang J; Smith SB; Topczewski JJ *ACS Med. Chem. Lett* 2019, 10, 1436–1442. [PubMed: 31620230]
- [5]. (a)Cativuela C; Díaz-de-Villegas MD *Tetrahedron Asymmetry* 1998, 9, 3517–3599.(b)Cativuela C; Díaz-de-Villegas MD *Tetrahedron Asymmetry* 2007, 18, 569–623.(c)Vogt H; Bräse S *Org. Biomol. Chem* 2007, 5, 406–430. [PubMed: 17252120] (d)Nájera C; Sansano JM *Chem. Rev*

- 2007, 107, 4584–4671. [PubMed: 17915933] (e)Metz AE; Kozlowski MC J. *Org. Chem* 2015, 80, 1–7. [PubMed: 25496236]
- [6]. (a)Trost BM; Ariza X *Angew. Chem. Int. Ed* 1997, 36, 2635–2637.(b)Trost BM; Dogra KJ *Am. Chem. Soc* 2002, 124, 7256–7257.(c)Chen W; Hartwig JF *J. Am. Chem. Soc* 2013, 135, 2068–2071. [PubMed: 23286279] (d)Wei X; Liu D; An Q; Zhang W *Org. Lett* 2015, 17, 5768–5771. [PubMed: 26575242] (e)Su Y-L; Li Y-H; Chen Y-G; Han Z-Y *Chem. Commun* 2017, 53, 1985–1988.(f)Huo X; Zhang J; Fu J; He R; Zhang WJ *Am. Chem. Soc* 2018, 140, 2080–2084.(g)Wei L; Zhu Q; Xu S-M; Chang X; Wang C-J *Am. Chem. Soc* 2018, 140, 1508–1513.(h)Wu H-M; Zhang Z; Xiao F; Wei L; Dong X-Q; Wang C-J *Org. Lett* 2020, 22, 4852–4857. [PubMed: 32506915]
- [7]. (a)Zhang Q; Yu H; Shen L; Tang T; Dong D; Chai W; Zi WJ *Am. Chem. Soc* 2019, 141, 14554–14559.(b)For related studies, see: Goldfogel MJ; Meek SJ *Chem. Sci* 2016, 7, 4079–4084. [PubMed: 30155052] (c)Zhang Z; Xiao F; Wu H-M; Dong X-Q; Wang C-J *Org. Lett* 2020, 22, 569–574. [PubMed: 31895576]
- [8]. Trost BM *Science* 1991, 254, 1471–1477. [PubMed: 1962206]
- [9]. Kitadai N; Maruyama S *Geosci. Front* 2018, 9, 1117–1153.
- [10]. (a)For reviews, see: Haydl AM; Breit B; Liang T; Krische MJ *Angew. Chem. Int. Ed* 2017, 56, 11312–11325.(b)Koschker P; Breit B *Acc. Chem. Res* 2016, 49, 1524–1536. [PubMed: 27455048] (c)Thoke MB; Kang Q *Synthesis* 2019, 51, 2585–2631.(d)Li G; Huo X; Jiang X; Zhang W *Chem. Soc. Rev* 2020, 49, 2060–2118. [PubMed: 32150186] (e)For examples, see: Kadota I; Shibuya A; Gyoung YS; Yamamoto YJ *Am. Chem. Soc* 1998, 120, 10262–10263. (f)Patil NT; Kadota I; Shibuya A; Gyoung YS; Yamamoto Y *Adv. Synth. Catal* 2004, 346, 800–804.(g)Yang C; Zhang K; Wu Z; Yao H; Lin A *Org. Lett* 2016, 18, 5332–5335. [PubMed: 27684319] (h)Obora Y; Hatanaka S; Ishii Y *Org. Lett* 2009, 11, 3510–3513. [PubMed: 19719194] (i)Park BY; Nguyen KD; Chaulagain MR; Komanduri V; Krische MJ *J. Am. Chem. Soc* 2014, 136, 11902–11905. [PubMed: 25075434] (j)Liang T; Zhang W; Krische MJ *J. Am. Chem. Soc* 2015, 137, 16024–16027. [PubMed: 26671223]
- [11]. Wolf J; Werner H *Organometallics* 1987, 6, 1164–1169.
- [12]. (a)Chen Q-A; Chen Z; Dong VM *J. Am. Chem. Soc* 2015, 137, 8392–8395. [PubMed: 26107923] (b)Haydl AM; Hilpert LJ; Breit B *Chem. Eur. J* 2016, 22, 6547–6551. [PubMed: 26990445] (c)Berthold D; Breit B *Org. Lett* 2018, 20, 598–601. [PubMed: 29350041] (d)Liu Z; Breit B *Angew. Chem. Int. Ed* 2016, 55, 8440–8443.(e)Koschker P; Kähny M; Breit BJ *Am. Chem. Soc* 2015, 137, 3131–3137.
- [13]. (a)Cruz FA; Dong VM *J. Am. Chem. Soc* 2017, 139, 1029–1032. [PubMed: 28074655] (b)Cruz FA; Zhu Y; Tercentio QD; Shen Z; Dong VM *J. Am. Chem. Soc* 2017, 139, 10641–10644. [PubMed: 28742333] (c)Xie L; Yang H; Ma M; Xing D *Org. Lett* 2020, 22, 2007–2011. [PubMed: 32065530] (d)For a related study, see: Ji D-W; Yang F; Chen B-Z; Min X-T; Kuai C-S; Hu Y-C; Chen Q-A *Chem. Commun* 2020, 56, 8468–8471.
- [14]. (a)Cruz FA; Chen Z; Kurtoic SI; Dong VM *Chem. Commun* 2016, 52, 5836–5839.(b)Li C; Grugel CP; Breit B *Chem. Commun* 2016, 52, 5840–5843.(c)Beck TM; Breit B *Eur. J. Org. Chem* 2016, 35, 5839–5844.(d)Beck TM; Breit B *Org. Lett* 2016, 18, 124–127. [PubMed: 26683497] (e)Zheng W-F; Xu Q-J; Kang Q *Organometallics* 2017, 36, 2323–2330.
- [15]. (a)Keller E; Veldman N; Spek AL; Feringa BL *Tetrahedron Asymmetry* 1997, 8, 3403–3413. (b)Keller E; Feringa BL *Synlett* 1997, 7, 842–844.
- [16]. Kornblum N; Blackwood RK; Powers JW *J. Am. Chem. Soc* 1957, 10, 2507–2509.
- [17]. On the basis of Zi's report (reference 7a), we investigated an aldimine ester and found that it does not couple to alkyne 2a under the standard conditions.
- [18]. (a)Ohmatsu K; Ito M; Kunieda T; Ooi T *Nat. Chem* 2012, 4, 473–477. [PubMed: 22614382] (b)For related studies, see: Sawamura M; Nakayama Y; Tang W-M; Ito YJ *Org. Chem* 1996, 61, 9090–9096.(c)Maki K; Kanai M; Shibasaki M *Tetrahedron* 2007, 63, 4250–4257.(d)Trost BM; Surivet J-P *Angew. Chem. Int. Ed* 2000, 39, 3122–3124.(e)Trost BM; Surivet J-P *J. Am. Chem. Soc* 2000, 122, 6291–6262.
- [19]. (a)For reviews, see: Shipchandler MT *Synthesis* 1979, 9, 666–686.(b)Ono N, *The Nitro Group in Organic Synthesis*, Wiley, New York, 2001.(c)For examples, see: Li H; Wang Y; Tang L; Wu F; Liu X; Guo C; Foxman BM; Deng L *Angew. Chem. Int. Ed* 2005, 44, 105–108.(d)Sing A;


Johnston JN *J. Am. Chem. Soc.* 2008, 130, 5866–5867. [PubMed: 18410096] (e)Chen Z; Morimoto H; Matsunaga S; Shibasaki MJ *Am. Chem. Soc.* 2008, 130, 2170–2171. (f)Uraguchi D; Koshimoto K; Ooi TJ *Am. Chem. Soc.* 2008, 130, 10878–10879. (g)Cui H-F; Li P; Wang X-W; Chai Z; Yang Y-Q; Cai YP; Zhu S-Z; Zhao G *Tetrahedron* 2011, 67, 312–317. (h)Shirakawa S; Terao SJ; He R; Maruoka K *Chem. Commun.* 2011, 47, 10557–10559. (i)Li Y-Z; Li F; Tian P; Lin G-Q *Eur. J. Org. Chem.* 2013, 1558–1565. (j)Zhu Q; Meng B; Gu C; Xu Y; Chen J; Lei C; Wu X *Org. Lett.* 2019, 21, 9985–9989. [PubMed: 31820655]

- [20]. For an example of enantioselectivity changing as a function of ligand dihedral angle, see: Shimizu H; Nagasaki I; Matsumura K; Sayo N; Saito T *Acc. Chem. Res.* 2007, 40, 1385–1393. [PubMed: 17685581]
- [21]. See the Supporting Information for more details.
- [22]. CCDC 2014416 (3fa) and CCDC 2014415 (3ao) contain the supplementary crystallographic data for this report. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre. The absolute configurations of the remaining allylic  $\alpha$ -AA precursors **3** were assigned by analogy.
- [23]. (a)Giuseppe AD; Castarlenas R; Pérez-Torrente JJ; Crucianelli M; Polo V; Sancho R; Lahoz FJ; Oro LA *J. Am. Chem. Soc.* 2012, 134, 8171–8183. [PubMed: 22536797] (b)Giuseppe AD; Castarlenas R; Pérez-Torrente JJ; Lahoz FJ; Oro LA *Chem. Eur. J.* 2014, 20, 8391–8403. [PubMed: 24895153] (c)Yang X-H; Davison RT; Nie S-Z; Cruz FA; McGinnis TM; Dong VM *J. Am. Chem. Soc.* 2019, 141, 3006–3013. [PubMed: 30735362]
- [24]. (a)Osakada K; Choi J-C; Koizumi T-A; Yamaguchi I; Yamamoto T *Organometallics* 1995, 14, 4962–4965. (b)Takagi K; Tomita I; Endo T *Macromolecules* 1997, 30, 7386–7390.
- [25]. In agreement with this statement, when we lower the amount of allene used to 0.3 equivalents, we observe **3aa** in 48% yield.
- [26]. (a)Lin YA; Chalker JM; Davis BG *ChemBioChem* 2009, 10, 959–969. [PubMed: 19343741] (b)deGruyter JN; Malins LR; Baran PS *Biochemistry* 2017, 56, 3863–3873. [PubMed: 28653834]
- [27]. Gamblin DP; Scanlan EM; Davis BG *Chem. Rev.* 2009, 109, 131–163. [PubMed: 19093879]
- [28]. White CJ; Yudin AK *Nat. Chem.* 2011, 3, 509–524. [PubMed: 21697871]


— **Inspiration:** biologically active  $\alpha,\alpha$ -disubstituted  $\alpha$ -AAs and analogs —



$\alpha$ -methyl-L-Phe  
( $\beta$ -turn former)





methyl dopa (aldomet)  
(antihypertensive)



3-amino-chromane  
(lead for  $\alpha_1$  receptor)

— **Hydrofunctionalization:** synthesis of  $\alpha$ -AAs with contiguous stereocenters —



**Figure 1.**  
Inspiration for the enantioselective addition of  $\alpha$ -nitroesters to alkynes.








Figure 2.  
Proposed mechanism for Rh-catalyzed allylation.

## A. Isotope Labeling Study




## B. Allene Intermediate Study




**Figure 3.**  
Mechanistic studies.

Table 1.

Investigating various  $\alpha$ -nitrocarbonyls.<sup>[a]</sup>

<sup>[a]</sup> **1** (0.10 mmol), **2a** (0.15 mmol),  $[\text{Rh}(\text{cod})\text{Cl}]_2$  (4.0 mol%), dppf (8.0 mol%),  $(\text{PhO})_2\text{P}(\text{O})\text{OH}$  (20 mol%), DCE (0.20 mL), 80 °C, 24 h. Yields determined by <sup>1</sup>H NMR referenced to an internal standard. Cod = 1,5-cyclooctadiene, dppf = 1,1'-bis(diphenylphosphino)ferrocene, DCE = 1,2-dichloroethane.


Table 2.

Survey of chiral ligands.<sup>[a]</sup>

<sup>[a]</sup> **1a** (0.10 mmol), **2a** (0.15 mmol),  $[\text{Rh}(\text{cod})\text{Cl}]_2$  (4.0 mol%), chiral ligand (8.0 mol%),  $(\text{PhO})_2\text{P}(\text{O})\text{OH}$  (20 mol%), DCE (0.20 mL), 80 °C, 24 h.


Yields determined by <sup>1</sup>H NMR referenced to an internal standard. [b] Isolated yield for a 1 mmol reaction.

Table 3.

 $\alpha$ -Nitrocarbonyl scope.<sup>[a]</sup>

<sup>[a]</sup> **1** (0.10 mmol), **2a** (0.15 mmol), [Rh(cod)Cl]<sub>2</sub> (4.0 mol%), MeO-BIPHEP **L6** (8.0 mol%), (PhO)<sub>2</sub>P(O)OH (20 mol%), DCE (0.20 mL), 80 °C, 24 h. Isolated yields. [b] 6:1 *dr*. [c] Yields based on recovered starting material (brsm): **3ea** (76%), **3ga** (96%), and **3ha** (65%). [d] [Rh(cod)Cl]<sub>2</sub> (8 mol%) and **L6** (16 mol%) instead of standard conditions.

Table 4.

Alkyne scope.<sup>[a]</sup>

<sup>[a]</sup> **1a** (0.10 mmol), **2** (0.15 mmol),  $[\text{Rh}(\text{cod})\text{Cl}]_2$  (4.0 mol%), MeO-BIPHEP **L6** (8.0 mol%),  $(\text{PhO})_2\text{P}(\text{O})\text{OH}$  (20 mol%), DCE (0.20 mL), 80 °C, 24 h. Isolated yields. <sup>[b]</sup>  $[\text{Rh}(\text{cod})\text{Cl}]_2$  (7.5 mol%) and **L6** (15 mol%) instead of standard conditions. <sup>[c]</sup> 15:1 *dr*.